Myelosuppression is usually reversible, and treatment can be given every 3-4 wk. Contraindicated in patients shown to have previous hypersensitivity to ifosfamide. Urotoxicity consisted of hemorrhagic cystitis, dysuria, urinary frequency, and other symptoms of bladder irritation. Incidence of CNS toxicity may be higher in patients with renal dysfunction. Nausea and vomiting are usually controlled with use of standard antiemetics.
Drug is mutagenic in vivo and in vitro.
Safety and effectiveness not established. Based upon 2,070 patients from published literature in 30 single-agent studies. The information provided above is based on the manufacturer's official US labeling for this product, last updated December 1998. Inc. All rights reserved.